Scholtz & Company LLC Buys New Stake in Vericel Corporation $VCEL

Posted by George Bondi on Sep 10th, 2026

Scholtz & Company LLC purchased a new position in Vericel Corporation (NASDAQ:VCEL – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 51,409 shares of the biotechnology company’s stock, valued at approximately $2,287,000. Vericel comprises 1.1% of Scholtz & Company LLC’s investment portfolio, making the stock its 29th largest position. Scholtz & Company LLC owned approximately 0.10% of Vericel at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. GAMMA Investing LLC raised its position in shares of Vericel by 17.7% during the 2nd quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company’s stock valued at $84,000 after buying an additional 283 shares in the last quarter. Osaic Holdings Inc. grew its position in Vericel by 13.7% in the second quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 353 shares in the last quarter. California State Teachers Retirement System increased its stake in Vericel by 0.8% during the second quarter. California State Teachers Retirement System now owns 45,404 shares of the biotechnology company’s stock worth $1,932,000 after acquiring an additional 382 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in Vericel by 3.6% during the fourth quarter. Commonwealth Equity Services LLC now owns 11,698 shares of the biotechnology company’s stock worth $421,000 after acquiring an additional 410 shares during the last quarter. Finally, Handelsbanken Fonder AB raised its position in Vericel by 2.2% during the second quarter. Handelsbanken Fonder AB now owns 23,079 shares of the biotechnology company’s stock valued at $1,027,000 after purchasing an additional 500 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on VCEL. Canaccord Genuity Group set a $60.00 target price on Vericel in a report on Thursday, July 30th. Truist Financial restated a “buy” rating and issued a $58.00 price target (up from $54.00) on shares of Vericel in a research report on Friday, July 31st. Wall Street Zen raised shares of Vericel from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Weiss Ratings upgraded shares of Vericel from a “sell (d+)” rating to a “hold (c)” rating in a research report on Friday, July 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of Vericel in a research note on Tuesday, July 28th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Vericel currently has an average rating of “Moderate Buy” and a consensus target price of $58.40.

Read Our Latest Report on VCEL

Insider Transactions at Vericel

In related news, insider Jonathan Hopper sold 10,000 shares of Vericel stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $45.00, for a total value of $450,000.00. Following the completion of the sale, the insider directly owned 75,753 shares in the company, valued at $3,408,885. The trade was a 11.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Sean Flynn sold 15,000 shares of the stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $40.21, for a total transaction of $603,150.00. Following the transaction, the insider owned 1,647 shares in the company, valued at approximately $66,225.87. The trade was a 90.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 52,232 shares of company stock worth $2,304,217. Corporate insiders own 7.60% of the company’s stock.

Vericel Stock Performance

Vericel stock opened at $38.99 on Thursday. The company has a market capitalization of $2.00 billion, a PE ratio of 82.96 and a beta of 1.04. The company has a 50 day moving average price of $44.39 and a 200-day moving average price of $38.57. Vericel Corporation has a fifty-two week low of $28.95 and a fifty-two week high of $49.32.

Vericel (NASDAQ:VCEL – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.07. The company had revenue of $77.46 million for the quarter, compared to analysts’ expectations of $72.70 million. Vericel had a return on equity of 6.91% and a net margin of 7.91%.Vericel’s revenue was up 22.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.01) earnings per share. On average, analysts forecast that Vericel Corporation will post 0.54 earnings per share for the current year.

Vericel Company Profile

(Free Report)

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.